|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CA2369292C
(en)
|
1999-04-09 |
2010-09-21 |
Kyowa Hakko Kogyo Co. Ltd. |
Method of modulating the activity of functional immune molecules
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
WO2002044394A2
(en)
*
|
2000-11-29 |
2002-06-06 |
University Of Southern California |
Targetet retoviral vectors for cancer immunotherapy
|
|
US20070122406A1
(en)
|
2005-07-08 |
2007-05-31 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
EP1587540B1
(en)
|
2003-01-09 |
2021-09-15 |
MacroGenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090123428A1
(en)
*
|
2003-04-21 |
2009-05-14 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
|
US20070178066A1
(en)
|
2003-04-21 |
2007-08-02 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
|
ES2366617T3
(es)
*
|
2003-04-21 |
2011-10-21 |
Epeius Biotechnologies Corporation |
Métodos y composiciones para el tratamiento de transtornos.
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
NZ545776A
(en)
|
2003-08-22 |
2009-05-31 |
Biogen Idec Inc |
Improved antibodies having altered effector function and methods for making the same
|
|
CA2565874C
(en)
|
2004-05-10 |
2017-10-03 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
WO2006085967A2
(en)
*
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
EA014226B1
(ru)
|
2004-07-26 |
2010-10-29 |
Байоджен Айдек Ма Инк. |
Антитела к cd154, их фрагменты и способы применения антител и фрагментов
|
|
BRPI0514068B8
(pt)
|
2004-08-04 |
2021-05-25 |
Applied Molecular Evolution Inc |
anticorpo anti-cd20, e, composição farmacêutica
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
BRPI0517837A
(pt)
*
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
WO2006105062A2
(en)
*
|
2005-03-29 |
2006-10-05 |
Verenium Corporation |
Altered antibody fc regions and uses thereof
|
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
AU2006236439B2
(en)
|
2005-04-15 |
2012-05-03 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
WO2012018687A1
(en)
|
2010-08-02 |
2012-02-09 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
CA2614181A1
(en)
*
|
2005-07-01 |
2007-01-11 |
Medimmune, Inc. |
An integrated approach for generating multidomain protein therapeutics
|
|
US7923538B2
(en)
|
2005-07-22 |
2011-04-12 |
Kyowa Hakko Kirin Co., Ltd |
Recombinant antibody composition
|
|
PL1919503T3
(pl)
|
2005-08-10 |
2015-04-30 |
Macrogenics Inc |
Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
|
|
CA2625619A1
(en)
|
2005-10-14 |
2007-04-26 |
Medimmune, Inc. |
Cell display of antibody libraries
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
DK2006381T3
(en)
|
2006-03-31 |
2016-02-22 |
Chugai Pharmaceutical Co Ltd |
PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
|
|
CA2656224C
(en)
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
|
EP2505209A1
(en)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-specific antibodies and methods of the use thereof
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
AU2013202392B2
(en)
*
|
2006-12-20 |
2016-02-25 |
Mmrglobal, Inc. |
Antibodies and methods for making and using them
|
|
CA2832111A1
(en)
*
|
2006-12-20 |
2008-07-03 |
Mmrglobal, Inc. |
Antibodies and methods for making and using them
|
|
PL2125894T3
(pl)
|
2007-03-22 |
2019-08-30 |
Biogen Ma Inc. |
Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania
|
|
BRPI0811466A2
(pt)
|
2007-05-07 |
2014-10-14 |
Medimmune Llc |
Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
|
|
EP2626371A1
(en)
|
2007-07-31 |
2013-08-14 |
MedImmune, LLC |
Multispecific epitope binding proteins and uses thereof
|
|
CA2696627C
(en)
|
2007-08-17 |
2016-09-27 |
Purdue Research Foundation |
Psma binding ligand-linker conjugates and methods for using
|
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
|
US8795667B2
(en)
|
2007-12-19 |
2014-08-05 |
Macrogenics, Inc. |
Compositions for the prevention and treatment of smallpox
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
EP3211010A1
(en)
|
2007-12-21 |
2017-08-30 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (il-4r) - 173
|
|
ES2742268T3
(es)
|
2007-12-26 |
2020-02-13 |
Xencor Inc |
Variantes de Fc con unión alterada a FcRn
|
|
MX2010007767A
(es)
|
2008-01-18 |
2010-08-09 |
Medimmune Llc |
Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
SG189730A1
(en)
|
2008-04-02 |
2013-05-31 |
Macrogenics Inc |
Her2/neu-specific antibodies and methods of using same
|
|
JP5785490B2
(ja)
|
2008-04-02 |
2015-09-30 |
マクロジェニクス，インコーポレーテッド |
Ｂｃｒ複合体特異的抗体およびその使用方法
|
|
PT2708559T
(pt)
|
2008-04-11 |
2018-05-16 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
|
|
EP2280997A2
(en)
|
2008-04-18 |
2011-02-09 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
|
EP2318048B1
(en)
*
|
2008-07-21 |
2019-05-29 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
|
CA2739429C
(en)
*
|
2008-10-14 |
2020-12-22 |
Lisa A. Damico |
Immunoglobulin variants and uses thereof
|
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
KR101808602B1
(ko)
|
2009-10-07 |
2017-12-13 |
마크로제닉스, 인크. |
푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법
|
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
|
US9951324B2
(en)
|
2010-02-25 |
2018-04-24 |
Purdue Research Foundation |
PSMA binding ligand-linker conjugates and methods for using
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
US9150656B2
(en)
|
2010-03-04 |
2015-10-06 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
|
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
US20130177555A1
(en)
|
2010-08-13 |
2013-07-11 |
Medimmune Limited |
Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
|
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
NZ607510A
(en)
|
2010-09-10 |
2014-10-31 |
Apexigen Inc |
Anti-il-1 beta antibodies and methods of use
|
|
WO2012054654A2
(en)
*
|
2010-10-20 |
2012-04-26 |
Morphotek, Inc. |
Anti-folate receptor alpha antibody glycoforms
|
|
LT2647707T
(lt)
|
2010-11-30 |
2018-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Citotoksiškumą indukuojantis terapinis agentas
|
|
MX365235B
(es)
|
2010-11-30 |
2019-05-28 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
|
|
DK2663579T3
(en)
|
2011-01-14 |
2017-07-31 |
Univ California |
THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
|
|
CA2827170A1
(en)
|
2011-02-11 |
2012-08-16 |
David M. Hilbert |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
EP3604330A1
(en)
|
2011-02-25 |
2020-02-05 |
Chugai Seiyaku Kabushiki Kaisha |
Fcgammariib-specific fc antibody
|
|
BR112013021863A2
(pt)
|
2011-03-03 |
2016-11-22 |
Apexigen Inc |
anticorpos anti-receptor il-6 e métodos de uso
|
|
EP2683740B1
(en)
|
2011-03-10 |
2018-07-04 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
|
ES2608835T3
(es)
|
2011-04-13 |
2017-04-17 |
Bristol-Myers Squibb Company |
Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
|
|
CN103635488B
(zh)
|
2011-04-29 |
2016-12-14 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
WO2012162068A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
|
MX340498B
(es)
|
2011-06-30 |
2016-07-11 |
Chugai Pharmaceutical Co Ltd |
Polipeptido heterodimerizado.
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
JP5944994B2
(ja)
|
2011-08-12 |
2016-07-05 |
オメロス コーポレーション |
抗ｆｚｄ１０モノクローナル抗体およびそれらの使用方法
|
|
CN110680920A
(zh)
|
2011-09-30 |
2020-01-14 |
中外制药株式会社 |
诱导针对靶抗原的免疫应答的抗原结合分子
|
|
EP3210625B1
(en)
|
2011-09-30 |
2019-08-28 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
|
|
EP2762493B1
(en)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
|
CA3186128A1
(en)
*
|
2011-09-30 |
2013-04-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
US11851476B2
(en)
|
2011-10-31 |
2023-12-26 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
|
BR112014010774A2
(pt)
|
2011-11-02 |
2017-06-13 |
Apexigen Inc |
anticorpos anti-kdr e métodos de uso
|
|
ES2749349T3
(es)
|
2011-11-07 |
2020-03-19 |
Medimmune Llc |
Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
|
|
BR112014013081A2
(pt)
*
|
2011-11-30 |
2020-10-20 |
Chugai Seiyaku Kabushiki Kaisha |
veículo contendo fármaco em célula para formação de um complexo imune
|
|
WO2013093809A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
|
KR102041412B1
(ko)
*
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
KR102475951B1
(ko)
*
|
2012-02-24 |
2022-12-08 |
추가이 세이야쿠 가부시키가이샤 |
ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
|
|
US9751942B2
(en)
|
2012-03-29 |
2017-09-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-LAMP5 antibody and utilization thereof
|
|
DK2857419T3
(da)
|
2012-05-30 |
2021-03-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-bindende molekyle til eliminering af aggregerede antigener
|
|
US20150166654A1
(en)
|
2012-05-30 |
2015-06-18 |
Chugai Seiyaku Kabushiki Kaisha |
Target tissue-specific antigen-binding molecule
|
|
CN104736174B
(zh)
*
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
|
ES2758979T3
(es)
*
|
2012-07-06 |
2020-05-07 |
Genmab Bv |
Proteína dimérica con mutaciones triples
|
|
SG11201408538PA
(en)
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
WO2014030750A1
(ja)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
|
TWI855488B
(zh)
*
|
2012-08-24 |
2024-09-11 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
EP2914627B1
(en)
|
2012-10-30 |
2021-04-07 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
|
AU2013342163B2
(en)
*
|
2012-11-08 |
2018-08-16 |
F. Hoffmann-La Roche Ltd |
IL-6 antagonists and uses thereof
|
|
KR102354613B1
(ko)
|
2012-11-15 |
2022-01-21 |
엔도사이트, 인코포레이티드 |
Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
|
|
ES2780398T3
(es)
|
2012-12-10 |
2020-08-25 |
Biogen Ma Inc |
Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos
|
|
EP3557260B1
(en)
|
2012-12-21 |
2022-05-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
|
|
TWI693073B
(zh)
|
2012-12-21 |
2020-05-11 |
日商中外製藥股份有限公司 |
對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
|
|
CN105102618B
(zh)
|
2012-12-27 |
2018-04-17 |
中外制药株式会社 |
异源二聚化多肽
|
|
KR20200024345A
(ko)
*
|
2013-01-10 |
2020-03-06 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
ES2870802T3
(es)
|
2013-02-12 |
2021-10-27 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas a elevado pH
|
|
US10183967B2
(en)
|
2013-02-12 |
2019-01-22 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
ES2882183T3
(es)
|
2013-03-14 |
2021-12-01 |
Univ Duke |
Moléculas biespecíficas que son inmunorreactivas con células efectoras inmunitarias que expresan un receptor activador
|
|
MX2015011670A
(es)
|
2013-03-15 |
2016-03-31 |
Biogen Ma Inc |
Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
|
|
WO2014144791A2
(en)
|
2013-03-15 |
2014-09-18 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
|
ES2708565T3
(es)
|
2013-03-15 |
2019-04-10 |
Atyr Pharma Inc |
Conjugados de Fc-histidil-ARNt sintetasa
|
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
|
EP3424530A1
(en)
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
SG11201508170TA
(en)
|
2013-04-02 |
2015-11-27 |
Chugai Pharmaceutical Co Ltd |
Fc REGION VARIANT
|
|
HK1223567A1
(zh)
|
2013-06-24 |
2017-08-04 |
中外制药株式会社 |
含有人源化抗上皮调节蛋白抗体作爲有效成分的腺癌以外的非小细胞肺癌的治疗药
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
AU2014312190A1
(en)
|
2013-08-28 |
2016-02-18 |
Bioasis Technologies Inc. |
CNS-targeted conjugates of antibodies
|
|
SG10202103140XA
(en)
|
2013-10-02 |
2021-05-28 |
Medimmune Llc |
Neutralizing anti-influenza a antibodies and uses thereof
|
|
HUE066137T2
(hu)
|
2013-10-18 |
2024-07-28 |
Novartis Ag |
A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
|
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
|
JP6464166B2
(ja)
|
2013-11-14 |
2019-02-06 |
エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． |
陽電子放出断層撮影用の化合物
|
|
TW202446953A
(zh)
|
2013-12-04 |
2024-12-01 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
|
WO2015085210A1
(en)
|
2013-12-06 |
2015-06-11 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
WO2015139020A2
(en)
|
2014-03-14 |
2015-09-17 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
KR102409014B1
(ko)
|
2014-05-08 |
2022-06-14 |
추가이 세이야쿠 가부시키가이샤 |
Gpc3 표적 치료제 요법이 유효한 환자에게 투여되는 gpc3 표적 치료제
|
|
US11505605B2
(en)
|
2014-05-13 |
2022-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
WO2015175874A2
(en)
*
|
2014-05-16 |
2015-11-19 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
|
DK3151921T3
(da)
|
2014-06-06 |
2019-12-02 |
Bristol Myers Squibb Co |
Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
|
|
GB201413913D0
(en)
|
2014-08-06 |
2014-09-17 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
CN107108721B
(zh)
|
2014-09-29 |
2021-09-07 |
杜克大学 |
包含hiv-1包膜靶向臂的双特异性分子
|
|
DK4268843T3
(da)
|
2014-11-07 |
2025-11-10 |
F Hoffmann La Roche Ltd |
Forbedrede IL-6-antistoffer
|
|
HRP20201756T8
(hr)
|
2014-11-21 |
2021-08-20 |
Bristol-Myers Squibb Company |
Antitijela koja sadrže modificirane regije teškog lanca
|
|
DK3221363T3
(da)
|
2014-11-21 |
2020-08-10 |
Bristol Myers Squibb Co |
Antistoffer mod cd73 og anvendelser deraf
|
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
|
HUE056489T2
(hu)
|
2014-12-19 |
2022-02-28 |
Chugai Pharmaceutical Co Ltd |
Anti-C5 antitestek és alkalmazási eljárások
|
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
US10188759B2
(en)
|
2015-01-07 |
2019-01-29 |
Endocyte, Inc. |
Conjugates for imaging
|
|
SG11201706014PA
(en)
|
2015-02-05 |
2017-08-30 |
Chugai Pharmaceutical Co Ltd |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
RS61907B1
(sr)
|
2015-04-06 |
2021-06-30 |
Subdomain Llc |
Polipeptidi koji sadrže de novo vezujući domen i njihova primena
|
|
LT3303396T
(lt)
|
2015-05-29 |
2023-01-10 |
Bristol-Myers Squibb Company |
Antikūnai prieš ox40 ir jų panaudojimo būdai
|
|
EP3322735A4
(en)
|
2015-07-15 |
2019-03-13 |
Zymeworks Inc. |
ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
|
|
AR105634A1
(es)
|
2015-09-18 |
2017-10-25 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos que se unen a il 8 y sus usos
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
MX2018006333A
(es)
*
|
2015-12-01 |
2018-08-01 |
Genmab Bv |
Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
|
|
JP7141336B2
(ja)
|
2015-12-25 |
2022-09-22 |
中外製薬株式会社 |
抗ミオスタチン抗体および使用方法
|
|
JP7219005B2
(ja)
|
2015-12-28 |
2023-02-07 |
中外製薬株式会社 |
Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
|
|
US20190046642A1
(en)
|
2016-02-23 |
2019-02-14 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonist formulations and uses thereof
|
|
KR20180118725A
(ko)
|
2016-03-04 |
2018-10-31 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd73 항체와의 조합 요법
|
|
EP3431102A4
(en)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
|
|
CN109153719B
(zh)
|
2016-03-15 |
2022-12-30 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
|
MX2018011219A
(es)
|
2016-03-16 |
2019-01-10 |
Merrimack Pharmaceuticals Inc |
Trail diseñado por ingenieria para terapia de cancer.
|
|
MY198114A
(en)
|
2016-04-15 |
2023-08-04 |
Macrogenics Inc |
Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
EA039084B1
(ru)
|
2016-05-09 |
2021-12-01 |
Бристол-Майерс Сквибб Компани |
Антитела к tl1a и их применения
|
|
AU2017297506A1
(en)
|
2016-07-14 |
2019-02-21 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
|
MA45715A
(fr)
|
2016-07-25 |
2019-05-29 |
Biogen Ma Inc |
Anticorps anti-hspa5 (grp78) et leurs utilisations
|
|
KR102777127B1
(ko)
|
2016-08-02 |
2025-03-07 |
비스테라, 인크. |
조작된 폴리펩티드 및 그의 용도
|
|
KR102538749B1
(ko)
|
2016-08-05 |
2023-06-01 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
|
CN109863170B
(zh)
|
2016-08-12 |
2024-08-16 |
詹森生物科技公司 |
具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
|
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
GB201619652D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
MX2019005772A
(es)
|
2016-11-23 |
2019-10-02 |
Bioverativ Therapeutics Inc |
Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
|
|
WO2018139623A1
(en)
|
2017-01-30 |
2018-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-sclerostin antibodies and methods of use
|
|
KR102573778B1
(ko)
|
2017-02-17 |
2023-08-31 |
브리스톨-마이어스 스큅 컴퍼니 |
알파-시뉴클레인에 대한 항체 및 그의 용도
|
|
BR112019017695A2
(pt)
|
2017-02-28 |
2020-04-07 |
Bristol-Myers Squibb Company |
uso de anticorpos anti-ctla-4 com adcc acentuada para acentuar a resposta imune a uma vacina
|
|
CN110352074B
(zh)
|
2017-02-28 |
2024-07-16 |
思进股份有限公司 |
用于偶联的半胱氨酸突变抗体
|
|
EP3606952A1
(en)
|
2017-04-07 |
2020-02-12 |
Miltenyi Biotec GmbH |
POLYPEPTIDES WITH MUTANT HUMAN IgG4
|
|
EP3612215B1
(en)
|
2017-04-20 |
2024-08-28 |
aTyr Pharma, Inc. |
Compositions for treating lung inflammation
|
|
EP3625251A1
(en)
|
2017-05-15 |
2020-03-25 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
|
IL270596B1
(en)
|
2017-05-25 |
2025-09-01 |
Bristol Myers Squibb Co |
Antibodies comprising modified heavy constant region for use in treating cancer
|
|
BR112019025583A2
(pt)
*
|
2017-06-05 |
2020-06-16 |
Janssen Biotech, Inc. |
Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3
|
|
PT3456736T
(pt)
*
|
2017-09-19 |
2021-05-28 |
Tillotts Pharma Ag |
Variantes de anticorpos
|
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
|
EP3694552A1
(en)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
|
AU2018368431B2
(en)
|
2017-11-14 |
2024-03-21 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
|
EP4640703A2
(en)
|
2017-11-14 |
2025-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibodies and methods of use
|
|
AU2018369639C1
(en)
|
2017-11-14 |
2025-04-03 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
US11773171B2
(en)
|
2017-12-19 |
2023-10-03 |
Surrozen Operating, Inc. |
WNT surrogate molecules and uses thereof
|
|
US11746150B2
(en)
|
2017-12-19 |
2023-09-05 |
Surrozen Operating, Inc. |
Anti-LRP5/6 antibodies and methods of use
|
|
CA3085596A1
(en)
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Anti-frizzled antibodies and methods of use
|
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
|
KR102813913B1
(ko)
|
2018-01-12 |
2025-05-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Tim3에 대한 항체 및 그의 용도
|
|
JP2021510740A
(ja)
*
|
2018-01-24 |
2021-04-30 |
ゲンマブ ビー．ブイ． |
ポリペプチド変種およびそれらの用途
|
|
JP2018138022A
(ja)
*
|
2018-02-23 |
2018-09-06 |
ゲンマブ ビー．ブイ． |
ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
|
|
KR20200132938A
(ko)
|
2018-03-15 |
2020-11-25 |
추가이 세이야쿠 가부시키가이샤 |
지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
|
|
MX2020009786A
(es)
|
2018-03-21 |
2020-10-12 |
Five Prime Therapeutics Inc |
Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
CR20250022A
(es)
|
2018-04-02 |
2025-02-25 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
|
|
CA3097381A1
(en)
|
2018-04-17 |
2019-10-24 |
Endocyte, Inc. |
Methods of treating cancer
|
|
JP7402541B2
(ja)
|
2018-05-03 |
2023-12-21 |
ユニバーシティ オブ ロチェスター |
抗インフルエンザノイラミニダーゼモノクローナル抗体およびその使用
|
|
JP7372237B2
(ja)
*
|
2018-06-04 |
2023-10-31 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
|
CN120623353A
(zh)
|
2018-07-05 |
2025-09-12 |
瑟罗泽恩奥普瑞汀公司 |
多特异性wnt替代分子和其用途
|
|
AU2019302454A1
(en)
|
2018-07-09 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to ILT4
|
|
US12091462B2
(en)
|
2018-07-11 |
2024-09-17 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic pH
|
|
EP3835321A4
(en)
|
2018-08-10 |
2022-11-02 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
|
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
|
KR20210096167A
(ko)
|
2018-11-28 |
2021-08-04 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 중쇄 불변 영역을 포함하는 항체
|
|
EP3892632A4
(en)
|
2018-12-05 |
2022-08-17 |
Bica Therapeutics Inc. |
MODIFIED PRODUCT OF FC DOMAIN OF ANTIBODIES
|
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
|
US11008395B2
(en)
|
2019-01-22 |
2021-05-18 |
Bristol Myers-Squibb Company |
Antibodies against IL-7R alpha subunit and uses thereof
|
|
CN113613676A
(zh)
|
2019-03-19 |
2021-11-05 |
中外制药株式会社 |
包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
|
|
BR112021020116A2
(pt)
|
2019-04-08 |
2021-12-07 |
Biogen Ma Inc |
Anticorpos anti-integrina e usos dos mesmos
|
|
EP3955960B1
(en)
|
2019-04-18 |
2025-01-15 |
Bristol-Myers Squibb Company |
Ipilimumab variants with enhanced specificity for binding at low ph
|
|
BR112021021689A2
(pt)
|
2019-05-15 |
2022-03-22 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação a antígeno, composição farmacêutica, e método
|
|
CN120097930A
(zh)
|
2019-05-20 |
2025-06-06 |
因多塞特股份有限公司 |
制备psma缀合物的方法
|
|
WO2021011678A1
(en)
|
2019-07-15 |
2021-01-21 |
Bristol-Myers Squibb Company |
Anti-trem-1 antibodies and uses thereof
|
|
JP2022540904A
(ja)
|
2019-07-15 |
2022-09-20 |
ブリストル－マイヤーズ スクイブ カンパニー |
ヒトｔｒｅｍ－１に対する抗体およびその使用
|
|
CN114729043A
(zh)
|
2019-09-19 |
2022-07-08 |
百时美施贵宝公司 |
在酸性pH下结合至VISTA的抗体
|
|
CA3179369A1
(en)
|
2020-04-01 |
2021-10-07 |
Kyowa Kirin Co., Ltd. |
Antibody composition
|
|
EP4126934A1
(en)
|
2020-04-01 |
2023-02-08 |
University of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
JP7048665B2
(ja)
*
|
2020-05-22 |
2022-04-05 |
ゲンマブ ビー．ブイ． |
ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
|
|
WO2021251438A1
(ja)
|
2020-06-10 |
2021-12-16 |
株式会社バイカ・セラピュティクス |
エリスロポエチンポリペプチドを含む融合タンパク質
|
|
AU2021306179A1
(en)
|
2020-07-10 |
2023-03-02 |
Invetx Inc. |
Compositions for increasing half-life of a therapeutic agent in felines and methods of use
|
|
EP4240758A1
(en)
|
2020-11-04 |
2023-09-13 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
|
CN114644708B
(zh)
|
2020-12-18 |
2023-06-27 |
珠海泰诺麦博生物技术有限公司 |
呼吸道合胞病毒特异性结合分子
|
|
US11479610B2
(en)
|
2020-12-23 |
2022-10-25 |
Cantargia Ab |
Anti-IL1RAP antibody
|
|
US12060411B2
(en)
|
2021-01-15 |
2024-08-13 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies
|
|
CN117425484A
(zh)
|
2021-03-26 |
2024-01-19 |
阿奇利克斯股份有限公司 |
多功能免疫细胞疗法
|
|
US20240376224A1
(en)
|
2021-04-02 |
2024-11-14 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
|
WO2023191766A1
(en)
*
|
2022-03-28 |
2023-10-05 |
Intervexion Therapeutics, Llc |
ANTIBODIES WITH ALTERED FcRn AFFINITY
|
|
PE20251075A1
(es)
|
2022-07-22 |
2025-04-10 |
Bristol Myers Squibb Co |
Anticuerpos que se unen a la pad4 humana y usos de los mismos
|
|
WO2024107749A1
(en)
|
2022-11-16 |
2024-05-23 |
Attralus, Inc. |
Fusion proteins that bind amyloid and the transferrin receptor and uses thereof
|
|
WO2024196694A2
(en)
*
|
2023-03-17 |
2024-09-26 |
Eli Lilly And Company |
Pd-1 agonist antibodies and methods of treating inflammatory or autoimmune skin diseases with a pd-1 agonist antibody
|
|
WO2024200573A1
(en)
|
2023-03-27 |
2024-10-03 |
LAVA Therapeutics N.V. |
Nectin-4 binding agents and methods of use
|
|
AU2024270136A1
(en)
|
2023-05-05 |
2025-11-20 |
Otsuka Pharmaceutical Co., Ltd. |
Anti-il1rap antibodies
|
|
WO2025012118A2
(en)
|
2023-07-07 |
2025-01-16 |
LAVA Therapeutics N.V. |
5t4 binding agents and methods of use
|
|
WO2025024265A1
(en)
|
2023-07-21 |
2025-01-30 |
Bristol-Myers Squibb Company |
Methods of assessing citrullination and activity of pad4 modulators
|
|
WO2025026282A1
(en)
*
|
2023-07-29 |
2025-02-06 |
Shanghai Kaijin Biotechnology, Ltd |
Modified type e multi-specific antibodies
|
|
WO2025072888A2
(en)
|
2023-09-28 |
2025-04-03 |
Novavax, Inc. |
Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
|
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
|
WO2025088546A1
(en)
*
|
2023-10-25 |
2025-05-01 |
Ablynx N.V. |
Fc domain variants with enhanced fc receptor binding
|
|
WO2025155877A2
(en)
|
2024-01-18 |
2025-07-24 |
The Regents Of The University Of California |
Antibodies binding to pad4 and uses thereof
|
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
|
EP4658320A1
(en)
|
2024-02-27 |
2025-12-10 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
EP4653010A1
(en)
|
2024-05-14 |
2025-11-26 |
35Pharma Inc. |
Activin receptor type iib traps for use in improving body composition
|
|
WO2025245176A1
(en)
|
2024-05-22 |
2025-11-27 |
Bristol-Myers Squibb Company |
Multispecific antibody constructs
|